Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
adrenergic blocker
advances in neurology
adverse drug reaction
alpha adrenergic blocker
anesthesia, general
anesthesia, local
antiarrhythmic drugs
antibiotics
antibiotics, neurologic complications with
anticonvulsants
anticonvulsants, untoward effects of
artane
autonomic dysfunction
benign essential tremor
benign sexual headache
beta adrenergic blocker
calcium antagonist
calcium antagonist, side effects of
children
chloroquine
clonidine
cluster headache
comorbidities
cyproheptidine
differential diagnosis
dilantin
diurnal variation
episodic disorders
ergotamine
facial pain
galcanezumab
headache
headache, children
headache, episodic
headache, prophylaxis
headache, severe
headache, treatment of
headache, unilateral
headache, vascular
hormone replacement
L-dopa
lithium
methysergide
midodrine
migraine
migraine, treatment of
misdiagnosis
monoamine oxidase inhibitors
monoclonal antibodies
myasthenia gravis
myasthenia gravis, drug induced
myasthenia gravis, unmasked
myasthenic syndrome
neuroleptic
neuromuscular blockade
nortriptyline
oral contraceptives
oral contraceptives, neurologic complications with
orthostatic hypotension, idiopathic
orthostatic hypotension, treatment of
penicillamine
phenothiazine
pizotifen
premarin
prevention of neurologic disorders
procainamide
progesterone
propranolol
quinidine
quinine
renal failure
review article
sexual intercourse
Shy-Drager syndrome
steroid
steroid therapy, CNS treatment and complications with
sumatriptan
tetanus antitoxin
timolol
treatment of neurologic disorder
tremor
trigeminovascular system
vagus nerve stimulation
verapamil
Showing articles 300 to 350 of 596 << Previous Next >>

Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010

New Drugs in Migraine Treatment and Prophylaxis: Telcagepant and Topiramate
Lancet 376:645-655, Edvinsson,L. &Linde,M., 2010

Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010

Acute Toxoplasmosis Infection in a Patient with Ankylosing Spondylitis Treated with Adalimumab: A Case Report
Reumatismo 62:283-285, Azevedo V.F., et al, 2010

Isolated Vein Thrombosis of the Posterior Fossa Presenting as Localized Cerebellar Venous Infarctions or Hemorrhages
Stroke 41:2358-2361, Ruiz-Sandoval, J.L.,et al, 2010

What if the sexual headache is not a joke?
BJMP 3:304-308, Redelman, M., 2010

Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009

Aicardi-Gouti�res Syndrome
Br Med Bull 89:183-201, Orcesi, S.,et al, 2009

Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009

May-Thurner Syndrome in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Stroke 40:1502-1504, Kiernan, T.J.,et al, 2009

Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009

Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009

Isolated Lateral Sinus Thrombosis: A Series of 62 Patients
Stroke 40:476-481, Damak,M.,et al, 2009

Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009

Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009

Assessment of Potential Drug Interactions in Patients with Epilepsy: Impact of Age and Sex
Neurol 72:419-425, Gidal,B.E.,et al, 2009

Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009

Stroke in Women: An Evolving Topic
Stroke 40:1027-1028, Kurth,T. &Bousser,M.-G., 2009

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009

Recurrent Pericarditis Due to Natalizumab Treatment
Neurol 72:1616-1617, Cohen,M.,et al, 2009

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009

Parkinsonism in HIV-Infected Patients on Highly Active Antiretroviral Therapy
Neurol 73:401-403, Tisch,S. &Brew,B., 2009

Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009

Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009

Clinical Spectrum of Ataxia-Telangiectasia in Adulthood
Neurol 73:430-437, Verhagen,M.M.M.,et al, 2009

Lamotrigine Kinetics Within the Menstrual Cycle, After Menopause, and with Oral Contraceptives
Neurol 73:1388-1393, Wegner,I.,et al, 2009

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009

Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009

Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009

Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009

Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009

Aicardi-Gouti�res Syndrome: Neuroradiologic Findings and Follow-up
AJNR 30:1971-1976, Uggetti,C.,et al, 2009

Migraine and Cardiovascular Disease: Systematic Review and Meta-Analysis
BMJ 339:b3914, Sch�rks,M.,et al, 2009

Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008

Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008

Lymphomatoid Granulomatosis Involving Central Nervous System Successfully Treated With Rituximab alone
Arch Neurol 65:662-665, Ishiura,H.,et al, 2008

Clinicopath Conf., Endheim-Chester Disease
NEJM 359:736-747, Case 25-2008, 2008

Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008

Initial Management of Epilepsy
NEJM 359:166-176, French,J.A. &Pedley,T.A., 2008

Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008

Second Consensus Statement on the Diagnosis of Multiple System Atrophy
Neurol 71:670-676, Gilman,S.,et al., 2008

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008

Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008

Response of Anti-NMDA Receptor Encephalitis Without Tumor to Immunotherapy Including Rituximab
Neurol 71:1921-1923, Ishiura,H.,et al, 2008

Treatment of Neuromyelitis Optica with Rituximab; Retrospective Analysis of 25 Patients
Arch Neurol 65:1443-1448, Jacob,A.,et al, 2008

Neurogenic Orthostatic Hypotension
NEJM 358:615-624, Freeman,R., 2008

a-Synuclein Gene Duplication Is Present in Sporadic Parkinson Disease
Neurol 70:43-49,7, Ahn,T.-B.,et al, 2008



Showing articles 300 to 350 of 596 << Previous Next >>